ArticleCureus2025
Integrated Advanced Echocardiographic and Biomarker Approach for the Early Detection of Atrial Cardiomyopathy in Middle-Aged Patients With Atrial Fibrillation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Atrial fibrillation (AF) and atrial cardiomyopathy (AtCM) share overlapping pathophysiological processes, with abnormalities in atrial structure and function being key contributors to disease progression. Aim This study aimed to assess echocardiographic parameters and circulating biomarkers in middle-aged AF patients without previously known overt heart disease, to explore early markers of atrial dysfunction and AtCM. Methods Prospective, consecutive patients (n = 970) who had been admitted for symptomatic AF to our hospital from January 2016 to January 2018 were screened for participation in the study. A total of 70 patients met the inclusion criteria: stable sinus rhythm, age between 40 and 60 years, and structurally normal hearts assessed by conventional two-dimensional echocardiography (2DE). They were separated into two groups: new-onset AF (n = 33) and recurrent episodes of paroxysmal AF (n = 37). Thirty age-matched healthy subjects were enrolled in the control group. All patients underwent 2DE assessment with volumetric and speckle-tracking analyses. Galectin-3, high-sensitivity troponin I (hsTnI), and high-sensitivity C-reactive protein (hsCRP) were measured. Results Significant structural and functional impairments were observed in both atria among AF patients, with the left atrium (LA) showing more pronounced abnormalities. Key parameters, such as LA reservoir and contractile strain, as well as electromechanical delay (EMD), were notably reduced. Individuals with paroxysmal AF exhibited elevated galectin-3 and hsTnI concentrations compared to both new-onset AF patients and controls, indicating more advanced fibrosis and myocardial stress. Furthermore, LA stiffness index and strain measures correlated strongly with galectin-3 levels. Conclusion In middle-aged patients without overt heart disease, advanced echocardiographic parameters (particularly strain and EMD), combined with biomarkers such as galectin-3 and hsTnI, represent sensitive markers for early atrial dysfunction and AtCM. The integration of these diagnostic tools may improve early detection, facilitate risk assessment, and support timely therapeutic interventions to prevent the progression of AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.